Favipiravir (6-Fluoro-3-hydroxypyrazine-2-carboxamide) is a modified pyrazine analog that was initially approved for therapeutic use in resistant cases of influenza. Not only does favipiravir inhibit replication of influenza A and B, but the drug has shown promise in the treatment of avian influenza, and may be an alternative option for influenza strains that are resistant to neuramidase inhibitors. Favipiravir has been investigated for the treatment of life-threatening pathogens such as Ebola virus, Lassa virus, and now COVID-19

Therapy Area: Antiviral
Form: Antiviral Tablet
Packaging: 1X10(400 mg), 1X34(200 mg), 1X10(800 mg)


Favipiravir 400 mg /Favipiravir 800 mg /Favipiravir 200 mg


The mechanism of action of favipiravir is novel compared to existing influenza antivirals that primarily prevent entry and exit of the virus from cells. The active favipiravir-RTP selectively inhibits RNA polymerase and prevents replication of the viral genome. There are several hypotheses as to how favipiravir-RTP interacts with RNA dependent RNA polymerase (RdRp). Some studies have shown that when favipiravir-RTP is incorporated into a nascent RNA strand, it prevents RNA strand elongation and viral proliferation. Studies have also found that the presence of purine analogs can reduce favipiravir’s antiviral activity, suggesting competition between favipiravir-RTP and purine nucleosides for RdRp binding. Although favipiravir was originally developed to treat influenza, the RdRp catalytic domain (favipiravir’s primary target), is expected to be similar for other RNA viruses. This conserved RdRp catalytic domain contributes to favipiravir’s broad-spectrum coverage. Favipiravir is incorporated into cells and converted to favipiravir ribofuranosyI-5-triphosphate (Favipiravir – RTP). The Triphosphate form, Favipiravir – RTP, inhibits the activity of RNA dependent RNA polymerase (RdRp) of RNA viruses. Rd Rp is responsible for the replication of viral RNA to create more copies of Virus. Thus by inhibiting Rd Rp, Favipiravir inhibits viral replication.


  • Mild to moderate COVID – 19
  • Influenza (both A & B)
  • Ebola (on trial)


Mild to moderate COVID-19 (Under restricted emergency use in India) – The recommended dose of Favipiravir for adults (>18 years) is a loading dose of 3,600 mg (1,800 mg BID) on day 1, followed by 1,600 mg per day (800 mg BID) From day 2 up to a maximum of day 14.


This information is for registered medical practitioner only. Anyone other than medical practitioner should consult medical practitioner before using this product.

Enquire About FAVIBEST

Fill the form below and we will get in touch with you

    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.